Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Delmar Pharmaceuticals Inc (DMPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
DelMar Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) will be discussing their earnings results in their Q2 Earnings Call to be held on November 14, 2017 at 4:30 PM...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the first quarter...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

VANCOUVER, British Columbia and MENLO PARK, Calif. , Nov. 13, 2017 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Mr. Saiid Zarrabian...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

VANCOUVER, British Columbia and MENLO PARK, Calif. , Nov. 7, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of new data at...

DMPI : 0.86 (+7.50%)
ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors

NEW YORK, NY / ACCESSWIRE / October 24, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance...

DMPI : 0.86 (+7.50%)
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today...

DMPI : 0.86 (+7.50%)
Investor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) will be discussing their earnings results in their Q4 Earnings Call to be held October 4, 2017 at 4:30 PM Eastern...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced its financial results...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

VANCOUVER, British Columbia and MENLO PARK, Calif. , Sept. 28, 2017 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

VANCOUVER, British Columbia and MENLO PARK, Calif. , Sept. 27, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it will be presenting an abstract...

DMPI : 0.86 (+7.50%)
CEO Jeffery Bacha Discusses DelMar's VOL-083 Clinical Trials and the Major Milestones Ahead

Jeffery Bacha, CEO of DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. Mr. Bacha discusses DelMar's VOL-083 phase 3 clinical trial chemotherapy...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it has closed on its previously...

DMPI : 0.86 (+7.50%)
Today's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / September 21, 2017 / U.S. markets closed at another record high on Wednesday as bank stocks surged after the Federal Reserve announcement kept the possibility of a December...

DMPI : 0.86 (+7.50%)
IONS : 54.15 (-0.39%)
DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

VANCOUVER, British Columbia , and MENLO PARK, Calif. , Sept. 18, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration...

DMPI : 0.86 (+7.50%)
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme

VANCOUVER, British Columbia and MENLO PARK, Calif. , Sept. 11, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on...

DMPI : 0.86 (+7.50%)

Van Meerten Stock Picks

My 5 Favorite Small Caps
This morning I wanted to find the 5 Small Cap Stocks that had the best returns over the past year but still appeared to have some more room to climb.
SEDG -0.20 , GDOT +0.11 , CTRL -1.36 , ESIO -0.65 , QNST +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.06% ) this morning are down 0.06% on concern Special Counsel Mueller's criminal investigation between Trump campaign officials and Russia is deepening. Two people familiar with the matter... Read More

Chart of the Day

Chart of the Day

D R Horton (DHI) is the Barchart Chart of the Day.  The home builder has a Trend Spotter buy signal, a Weighted Alpha of 77.13+ and gained 68.46% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with most contracts 4 – 6 1/2 cents higher, as Dec came back to only lose a half cent on the week. Pre-weekend profit taking gets some of the credit. The CFTC report on Friday showed the spec funds holding a new recor...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart